RecruitingNot Applicable

Role of Novel ILR in the Management of PVCs

United States50 participantsStarted 2022-04-20

Plain-language summary

This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients \> 18 years of age * Have a Medtronic LINQ II ILR * Willing and able to give written informed consent Exclusion Criteria: * History of myocardial infarction * Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or Computed tomography angiography (CTA). * History of cardiac arrest * With existing implantable defibrillators * Currently pregnant

What they're measuring

Identification of unrecognized myocarditis

Timeframe: 12 Months

Evaluation of efficacy of immunosuppressive therapy - PVC burden reduce

Timeframe: 12 Months

Evaluation of efficacy of immunosuppressive therapy - LVEF improvement

Timeframe: 12 Months

Associated atrial and ventricular arrhythmias

Timeframe: 12 Months

Trial details

NCT IDNCT06060548

SponsorKansas City Heart Rhythm Research Foundation

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09

Contact for this trial

Donita Atkins

816-651-1969 datkins@kchrf.com

View on ClinicalTrials.gov More PVC - Premature Ventricular Contraction trials